ecteinascidin 743 has been researched along with Ovarian Neoplasms in 93 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.15) | 18.2507 |
| 2000's | 14 (15.05) | 29.6817 |
| 2010's | 67 (72.04) | 24.3611 |
| 2020's | 10 (10.75) | 2.80 |
| Authors | Studies |
|---|---|
| Albert, S; Bessede, A; Blay, JY; Brahmi, M; Chakiba, C; Cousin, S; Croce, S; Floquet, A; Giraud, A; Guégan, JP; Italiano, A; Kind, M; Mathoulin-Pelissier, S; Perret, R; Pulido, M; Ray-Coquard, I; Toulmonde, M; Toulza, E | 1 |
| Coukos, G; Digklia, A; Homicsko, K | 1 |
| Bergamini, A; Bologna, A; Giolitto, S; Lorusso, D; Mangili, G; Mantero, M; Musacchio, L; Nicoloso, MS; Pignata, S; Pisano, C; Raspagliesi, F; Ronzulli, D; Salutari, V; Scambia, G; Tamberi, S | 1 |
| Avesani, G; Boccia, SM; Corrado, G; Fagotti, A; Marchetti, C; Scambia, G; Tiberi, G; Vertechy, L | 1 |
| Aglietta, M; Arcangeli, V; Barretina-Ginesta, MP; Benedetti Panici, P; Berger, R; Biagioli, E; Bologna, A; Chekerov, R; Churruca Galaz, C; Colombo, N; D'Incalci, M; De Giorgi, U; DeCensi, A; Deryal, M; Fossati, R; Funari, G; Gadducci, A; Heinzelmann-Schwarz, V; Herbertson, R; Iglesias, M; Mäenpää, J; Mirza, MR; Montes, A; Nyvang, GB; Ottevanger, NB; Pardo, B; Poveda, A; Riniker, S; Romeo, M; Rubio-Pérez, MJ; Rulli, E; Sehouli, J; Sessa, C; Tasca, G; Tognon, G; Tsibulak, I; Vergote, I; Westermann, A; Wimberger, P; Zamagni, C; Zola, P | 1 |
| Cao, D; Chen, H; Kossinna, P; Li, Q; Lin, C; Lin, J; Liu, GR; Liu, H; Liu, SL; Luo, Y; Wang, J; Wang, P; Wang, X; Wang, Y; Xie, K; Xu, M; Xu, X; Yang, H; Yang, J; Zeng, Z; Zhang, MC; Zhang, XH; Zhu, S | 1 |
| Baldoni, A; Biagioli, E; Colombo, N; D'Incalci, M; Farina, G; Ferrero, A; Fossati, R; Frezzini, S; Galli, F; Gerardi, C; Lissoni, AA; Negri, E; Palluzzi, E; Pesenti Gritti, A; Poli, D; Rubino, D; Rulli, E; Scambia, G; Tognon, G; Torri, V; Zaccarelli, E | 1 |
| Barra, F; Bifulco, G; D'Alessandro, G; Della Corte, L; Evangelisti, G; Ferrero, S; Stigliani, S; Tantari, M | 1 |
| Bourgeois, H; Brusa, F; Casado, A; De Rivas, B; de Sande, LM; Dopchie, C; Ibarbia, MA; Naglieri, E; Pignata, S; Reichert, D; Scambia, G; Sorio, R; Villanucci, A | 1 |
| González-Martín, A; Lorusso, D; Ray-Coquard, I | 1 |
| Coleman, RL; Demetri, GD; Herzog, TJ; Hu, P; Jones, RL; Knoblauch, R; McGowan, T; Monk, BJ; Patel, SR; Schuetze, SM; Shalaby, W; Triantos, S; Van Tine, BA; von Mehren, M | 1 |
| Amadio, G; de Vincenzo, R; Distefano, M; Ferrandina, G; Palluzzi, E; Paris, I; Ricci, C; Scambia, G | 1 |
| Allavena, P; Belgiovine, C; Bello, E; Beltrame, L; Craparotta, I; D'Incalci, M; Frapolli, R; Galmarini, CM; Liguori, M; Mannarino, L; Mantovani, A; Marchini, S; Paracchini, L | 1 |
| Adam, JP; Boumedien, F; Letarte, N; Provencher, D | 1 |
| Caratti, G; Colmegna, B; D'Incalci, M; Erba, E; Ferrari, M; Fruscio, R; Gobbi, M; Lorusso, D; Matteo, C; Mezzanzanica, D; Panini, N; Perlangeli, MV; Porcu, L; Raspagliesi, F; Romano, M; Zucchetti, M | 1 |
| Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
| Benedetti Panici, P; Boccia, S; De Felice, F; Di Donato, V; Marchetti, C; Monti, M; Musella, A; Muzii, L; Palaia, I; Romito, A; Vertechy, L | 1 |
| Bonetti, A; Giuliani, J | 1 |
| Colombo, N | 4 |
| C Cecere, S; Du Bois, A; Harter, P; Heitz, F; Pignata, S | 1 |
| Arenare, L; Califano, D; Cecere, SC; Di Napoli, M; Losito, NS; Orditura, M; Paciolla, I; Pignata, S; Pisano, C; Setola, SV; Ventriglia, J | 1 |
| Ray-Coquard, I | 2 |
| Marth, C | 1 |
| Alonso, T; Cabezas, S; Callata, HR; Casado, A; Díaz-Rubio, E; Fernández, C; Gajate, P; Manzano, A; Marquina, G; Sotelo, M | 1 |
| Arcusa, Á; Barretina-Ginesta, P; Bover, I; Casado, A; Del Campo, JM; García, Y; González-Martín, A; González-Santiago, S; Guerra, E; Herrero, A; Mallol, P; Martín, L; Martínez, A; Mori, M; Ortega, E; Romero, I; Rubio, MJ; Santaballa, A; Vicente, D; Vidal, L | 1 |
| Allavena, P; Anichini, A; Anselmo, A; Belgiovine, C; Beltrame, L; Casali, PG; D'Incalci, M; Erba, E; Frapolli, R; Fuso Nerini, I; Galmarini, CM; Germano, G; Liguori, M; Mantovani, A; Marchini, S; Mortarini, R; Nebuloni, M; Pasqualini, F; Pesce, S; Pilotti, S; Sanfilippo, R; Uboldi, S; van Rooijen, N; Zucchetti, M | 1 |
| Amadio, G; Carpano, S; Ferrandina, G; Loizzi, V; Lorusso, D; Marinaccio, M; Naglieri, E; Salutari, V; Scambia, G; Tonini, G; Vincenzi, B | 1 |
| Fisher, M; Gore, M | 1 |
| Clare, J | 1 |
| Poveda, A; Pujade-Lauraine, E | 1 |
| González, A | 1 |
| Sehouli, J | 1 |
| Aracil, M; Badri, N; Galmarini, CM; Herzog, TJ; Kaye, SB; Monk, BJ; Nieto, A; Parekh, TV; Poveda, A; Tanović, A | 1 |
| Colombo, N; Lopez-Guerrero, JA; Poveda, A; Ray-Coquard, I; Romero, I | 1 |
| Bazaeva, IIa; Cherkasova, MV; Gorbunova, VA; Khokhlova, SV; Limareva, SV; Orel, NF | 1 |
| Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T | 1 |
| Baracos, VE; Birdsell, L; Parekh, T; Park, YC; Prado, CM; Sawyer, MB; Stuyckens, K; Xiao, J | 1 |
| De Sarro, G; Di Paola, ED; Gallelli, L; Leporini, C; Lucia, M; Patanè, M; Rende, P; Rossi, M; Russo, E; Saullo, F; Toscano, R | 1 |
| López-Guerrero, JA; Poveda, A; Romero, I | 1 |
| Barton, S; Edwards, SJ; Thurgar, E; Trevor, N | 1 |
| Cheng, PS; Favis, R; Ghatage, P; Henitz, E; Knoblauch, R; Li, W; Matos-Pita, AS; Monk, BJ; Nieto, A; Parekh, T; Park, YC; Poveda, A; Ricci, D | 1 |
| Jahn, F; Jordan, B; Jordan, K; Kegel, T; Müller-Tidow, C; Rüssel, J | 1 |
| Guo, Z; Li, J; Meng, F; Wang, H; Zhang, S | 1 |
| Amadio, G; Artioli, G; Capoluongo, E; Di Napoli, M; Ferrandina, G; Gamucci, T; Lepori, S; Lorusso, D; Ludovini, V; Maltese, G; Mangili, G; Mosconi, A; Pignata, S; Pisano, C; Raspagliesi, F; Sabbatini, R; Scambia, G; Sorio, R | 1 |
| Bosacki, C; Espenel, S; Jacquin, JP; Magné, N; Méry, B; Moriceau, G; Pacaut, C; Rivoirard, R; Trone, JC; Vallard, A | 1 |
| Aglietta, M; Calogero, R; De Simone, M; Di Renzo, MF; Erriquez, J; Katsaros, D; Mittica, G; Olivero, M; Ponzone, R; Scalzo, MS; Vaira, M; Valabrega, G | 1 |
| Aracil, M; D'Incalci, M; Italiano, A; Kaye, SB; Lorusso, D; Monk, BJ; Tanović, A | 1 |
| Kim, HJ; Kim, JW; Kim, M; Lee, KH; Suh, DH | 1 |
| Colombo, N; Ferrandina, G; Hardy-Bessard, AC; Marth, C; Romero, I | 1 |
| du Bois, A; González-Martín, A | 1 |
| Arenare, L; Borgato, L; Cecere, SC; Della Pepa, C; Di Napoli, M; Ferrandina, G; Lepori, S; Lorusso, D; Mangili, G; Mosconi, AM; Pignata, S; Raspagliesi, F; Salutari, V; Salvino, A; Scambia, G; Sorio, R | 1 |
| Herzog, TJ; Teplinsky, E | 1 |
| Cuevas, C; Francesch, A | 1 |
| Capri, G; Corradino, I; Cresta, S; D'Incalci, M; De Braud, F; Gallerani, E; Gianni, L; Locatelli, A; Marsoni, S; Minoia, C; Noberasco, C; Sessa, C; Zintl, P; Zucchetti, M | 1 |
| Baconnier, M; Blay, JY; Boudou, L; Cassier, PA; Lombard-Bohas, C | 1 |
| Bidzinski, M; Boman, K; Ciuleanu, TE; Del Campo, JM; Hogberg, T; Lebedinsky, C; Poveda, A; Roszak, A; Westermann, AM; Wojtukiewicz, MZ | 1 |
| Carter, NJ; Keam, SJ | 2 |
| Bidzinski, M; Ghatage, P; Gorbounova, VA; Herzog, TJ; Kaye, SB; Krasner, CN; Lebedinsky, CA; Lisyanskaya, AS; Makhson, AN; Monk, BJ; Muggia, FM; Nam, JH; Ngan, HY; Park, YC; Poveda, AM; Pujade-Lauraine, E; Rolski, J; Shen, K; Vergote, IB; Vermorken, JB | 1 |
| Cannistra, SA | 1 |
| Del Campo, JM; Diaz de Corcuera, I; Muñoz-Couselo, E; Oaknin, A | 1 |
| Alfaro, V; Chan, S; Colombo, N; Filipczyk-Cisarz, E; Gómez, J; Hagberg, H; Kaye, SB; Kong, B; Lebedinsky, C; Monk, BJ; Parekh, T; Park, YC; Poveda, A; Roy, M; Tjulandin, S; Vergote, I | 1 |
| Chan, S; Colombo, N; Filipczyk-Cisarz, E; Hagberg, H; Kaye, SB; Kong, B; Lebedinsky, C; Monk, BJ; Nieto, A; Parekh, T; Park, YC; Poveda, A; Roy, M; Santabárbara, P; Tjulandin, S; Vergote, I | 1 |
| D'Incalci, M; Sessa, C | 1 |
| Bonebrake, AJ; De Geest, K; Edwards, R; Hanjani, P; Monk, BJ; Rotmensch, J; Sill, MW; Walker, JL | 1 |
| Poveda, A | 1 |
| González Martín, A | 1 |
| Evans, P; Papaioannou, D; Rafia, R; Stevens, JW; Stevenson, MD | 1 |
| Markman, M | 1 |
| Hayashi, M; Hisamatsu, T; Kawase, C; Kimura, T; Kurachi, H; Mabuchi, S; Mimura, K; Sawada, K; Takahashi, K; Takahashi, T | 1 |
| Kaye, SB; Lebedinsky, CA; McCormack, R; Monk, BJ; Parekh, T; Poveda, A; Ricci, D; Tercero, JC; Wang, S; Zintl, P | 1 |
| Alfaro, V; González-Martín, A; Sehouli, J | 1 |
| Herzog, TJ; Kaye, SB; Krasner, CN; Monk, BJ; Muggia, FM; Parekh, TV; Park, YC; Poveda, AM; Pujade-Lauraine, E; Vermorken, JB | 1 |
| Benjamin, I; Dalton, H; Monk, BJ; Tanović, A | 1 |
| Claret, PL; Herzog, TJ; Kaye, SB; Krasner, CN; Monk, BJ; Nieto, A; Parekh, T; Park, YC; Poveda, A; Vermorken, JB | 1 |
| Ikeda, Y; Kikuchi, Y; Kita, T; Kudoh, K; Sasaki, N; Takano, M | 1 |
| Colombo, N; del Campo, JM; Gómez, J; Gore, M; Kaye, S; Krasner, CN; McMeekin, S; Parekh, T; Park, YC; Sessa, C; Vermorken, JB; Zintl, P | 1 |
| Cavallini, E; Colombo, T; D'Incalci, M; Erba, E; Faircloth, GT; Ferrarese, L; Giavazzi, R; Jimeno, J; Meco, D; Nicoletti, I; Riccardi, R; Sessa, C; Ubezio, P | 1 |
| D'Incalci, M; Erba, E; Faircloth, GT; Frapolli, R; Tognon, G; Zaffaroni, M; Zucchetti, M | 1 |
| Bonomi, R; Broggini, M; Chiorino, G; D'Incalci, M; Faircloth, GT; Hornicek, FJ; Marchini, S; Marrazzo, E; Weissbach, L; Zaffaroni, M | 1 |
| Cavallaro, E; Cuevas, C; D'Incalci, M; Damia, G; Di Francesco, AM; Di Silvio, A; Erba, E; Faircloth, GT; Mantovani, R; Riccardi, R | 1 |
| Bauer, J; Colombo, N; Curigliano, G; D'Incalci, M; Dall'ó, E; De Braud, F; Gianni, L; Jimeno, J; Marsoni, S; Noberasco, C; Perotti, A; Sessa, C; Zanaboni, F | 1 |
| Sabbatini, P | 1 |
| Braly, PS; Campos, S; Chan, S; Gore, ME; Kaye, S; Krasner, CN; McMeekin, DS; Provencher, DM; Renshaw, FG | 1 |
| Antony, S; Kohn, EC; Munson, PJ; Nishizuka, S; Pommier, Y; Reimers, M; Stevens, EV; Varma, S; Weinstein, JN; Young, L | 1 |
| D'Incalci, M; Faircloth, G; Giavazzi, R; Hendriks, H; Jimeno, J; Nicoletti, MI; Pellegrino, A; Valoti, G | 1 |
| Faircloth, GT; Fiebig, HH; Giavazzi, R; Hendriks, HR; Jimeno, JM; Langdon, SP | 1 |
| Bassano, L; Bergamaschi, D; D'Incalci, M; Di Liberti, G; Erba, E; Faircloth, G; Jimeno, J; Muradore, I; Ronzoni, S; Vignati, S | 1 |
30 review(s) available for ecteinascidin 743 and Ovarian Neoplasms
| Article | Year |
|---|---|
When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Recurrence; Retreatment; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2017 |
Treatment of recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin | 2017 |
Trabectedin in Ovarian Cancer: is it now a Standard of Care?
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Standard of Care; Trabectedin | 2018 |
Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Trabectedin | 2018 |
Biology of ovarian cancer and trabectedin mechanism of action.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Female; Genes, BRCA1; Humans; Interleukin-6; Mutation; Ovarian Neoplasms; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2013 |
Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin | 2013 |
Increasing the chances for platinum-sensitive ovarian cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Recurrence; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2013 |
Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Practice Guidelines as Topic; Tetrahydroisoquinolines; Trabectedin | 2014 |
[Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoma, Ovarian Epithelial; Dioxoles; Doxorubicin; Drug Therapy, Combination; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Patient Selection; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2013 |
A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Drug Interactions; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2014 |
Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
Topics: Antineoplastic Agents, Alkylating; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Dioxoles; DNA Damage; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2015 |
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom | 2015 |
Trabectedin: Supportive care strategies and safety profile.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2015 |
Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Dioxoles; Doxorubicin; Female; Genes, BRCA1; Genes, BRCA2; Hereditary Breast and Ovarian Cancer Syndrome; Humans; Ovarian Neoplasms; Polyethylene Glycols; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
Major clinical research advances in gynecologic cancer in 2015.
Topics: Biomedical Research; Breast Neoplasms; Combined Modality Therapy; Dioxoles; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Papillomavirus Vaccines; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Uterine Cervical Neoplasms; Uterine Neoplasms | 2016 |
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Hypersensitivity; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Decision Making; Dioxoles; Doxorubicin; Female; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
The efficacy of trabectedin in treating ovarian cancer.
Topics: Antineoplastic Agents, Alkylating; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Discovery; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2017 |
Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
Topics: Animals; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Molecular Structure; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Tetrahydroisoquinolines; Trabectedin; Urochordata | 2009 |
Trabectedin for the management of soft-tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Controlled Clinical Trials as Topic; Dioxoles; DNA Repair; Female; Humans; Liver; Neutropenia; Ovarian Neoplasms; Sarcoma; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin; Transaminases | 2009 |
Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2010 |
Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dioxoles; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Tetrahydroisoquinolines; Trabectedin | 2010 |
Introduction. Trabectedin treatment in GYN cancers.
Topics: Animals; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Ovarian Neoplasms; Tetrahydroisoquinolines; Trabectedin; Urochordata | 2011 |
Safety profile of trabectedin in combination with liposomal pegylated doxorrubicin in relapsed ovarian carcinoma: considerations for optimal management.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dioxoles; Doxorubicin; Female; Humans; Liposomes; Ovarian Neoplasms; Patient Compliance; Quality of Life; Recurrence; Tetrahydroisoquinolines; Trabectedin | 2011 |
Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Multicenter Studies as Topic; Ovarian Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic; Recurrence; Tetrahydroisoquinolines; Trabectedin | 2011 |
Trabectedin for the treatment of relapsed ovarian cancer.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Doxorubicin; Female; Humans; Mesalamine; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Tetrahydroisoquinolines; Trabectedin | 2011 |
Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dioxoles; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Randomized Controlled Trials as Topic; Salvage Therapy; Tetrahydroisoquinolines; Trabectedin | 2012 |
Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
Topics: Antineoplastic Agents; Dioxoles; Female; Humans; Ovarian Neoplasms; Recurrence; Tetrahydroisoquinolines; Trabectedin | 2012 |
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Vomiting | 2013 |
Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2007 |
22 trial(s) available for ecteinascidin 743 and Ovarian Neoplasms
| Article | Year |
|---|---|
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Progression-Free Survival; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2022 |
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 month
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Trabectedin | 2023 |
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Progression-Free Survival; Survival Rate; Trabectedin | 2019 |
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Europe; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Prospective Studies; Trabectedin | 2021 |
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Decision Support Techniques; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Models, Theoretical; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Survival Analysis; Survival Rate; Tetrahydroisoquinolines; Trabectedin; United Kingdom | 2013 |
Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.
Topics: Biomarkers; Cell Cycle Proteins; Cystadenocarcinoma, Serous; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nuclear Proteins; Ovarian Neoplasms; Polyethylene Glycols; Proportional Hazards Models; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Body Composition; Dexamethasone; Dioxoles; Doxorubicin; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome | 2014 |
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Dioxoles; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Pharmacogenetics; Polyethylene Glycols; Tetrahydroisoquinolines; Time Factors; Trabectedin; Transcription Factors; Treatment Outcome | 2015 |
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; BRCA1 Protein; BRCA2 Protein; Dioxoles; Disease-Free Survival; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Prospective Studies; Tetrahydroisoquinolines; Trabectedin | 2016 |
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dioxoles; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neutropenia; Ovarian Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2009 |
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Tetrahydroisoquinolines; Trabectedin | 2009 |
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Polyethylene Glycols; Stomatitis; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2010 |
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Ovarian Neoplasms; Polyethylene Glycols; Recurrence; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2011 |
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Polyethylene Glycols; Recurrence; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2011 |
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2011 |
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimes: a phase II study of the Gynecologic Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2011 |
Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Ovarian Neoplasms; Polyethylene Glycols; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2011 |
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Survival Analysis; Tetrahydroisoquinolines; Trabectedin | 2012 |
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Longitudinal Studies; Ovarian Neoplasms; Polyethylene Glycols; Surveys and Questionnaires; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2012 |
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Dioxoles; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Isoquinolines; Middle Aged; Ovarian Neoplasms; Salvage Therapy; Taxoids; Tetrahydroisoquinolines; Trabectedin; Treatment Failure | 2005 |
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
Topics: Adolescent; Adult; Dioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2007 |
41 other study(ies) available for ecteinascidin 743 and Ovarian Neoplasms
| Article | Year |
|---|---|
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study.
Topics: Antibodies, Monoclonal; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2022 |
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2022 |
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Case-Control Studies; Disease Progression; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Trabectedin | 2023 |
Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Female; Humans; Mice; Ovarian Neoplasms; Thrombospondin 1; Trabectedin; Vascular Endothelial Growth Factor A | 2023 |
Trabectedin for the therapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2020 |
Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Trabectedin | 2021 |
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cardiovascular Diseases; Child; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Doxorubicin; Female; Heart; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Product Surveillance, Postmarketing; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Stroke Volume; Trabectedin; Ventricular Function, Left; Young Adult | 2021 |
Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Italy; Neoplasm Recurrence, Local; Oncologists; Ovarian Neoplasms; Polyethylene Glycols; Practice Patterns, Physicians'; Surveys and Questionnaires; Tetrahydroisoquinolines; Trabectedin | 2017 |
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Carbolines; Caspase 8; Cell Adhesion; Cell Movement; Chemokine CCL2; Dioxoles; Down-Regulation; Female; Fibrosarcoma; Gene Expression; Gene Expression Profiling; Heterocyclic Compounds, 4 or More Rings; HL-60 Cells; Humans; Interleukin-8; Leukocyte Count; Macrophages; Mice; Mice, Inbred C57BL; Monocytes; Neovascularization, Pathologic; Ovarian Neoplasms; rho GTP-Binding Proteins; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment; U937 Cells; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |
Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma; Dioxoles; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin | 2017 |
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.
Topics: Animals; Antineoplastic Agents, Alkylating; Ascites; Carbolines; Cell Line, Tumor; Dioxoles; Dose-Response Relationship, Drug; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Mice, Nude; Orosomucoid; Ovarian Neoplasms; Protein Binding; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Case-Control Studies; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin | 2017 |
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2017 |
Management of relapsed ovarian cancer in routine clinical practice: a case study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Care Team; Platinum Compounds; Polyethylene Glycols; Trabectedin; Treatment Outcome | 2018 |
Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Trabectedin; Treatment Outcome | 2018 |
Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies; Trabectedin | 2019 |
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Retrospective Studies; Survival Rate; Trabectedin | 2019 |
Role of macrophage targeting in the antitumor activity of trabectedin.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Carcinoma, Lewis Lung; Caspase 8; Cell Proliferation; Dioxoles; Female; Fibrosarcoma; Flow Cytometry; Humans; Immunoenzyme Techniques; Macrophages; Mice; Monocytes; Myeloid Cells; Neovascularization, Pathologic; Ovarian Neoplasms; Phagocytes; Signal Transduction; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured | 2013 |
Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Asthenia; Carcinoma; Dioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies; Salvage Therapy; Tetrahydroisoquinolines; Trabectedin | 2013 |
Trabectedin plus pegylated liposomal doxorubicin: the return of a treatment option for ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin | 2013 |
Introduction: 1 year of silence?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin | 2013 |
Conclusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin | 2013 |
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured | 2014 |
Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Topics: Animals; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytotoxicity, Immunologic; Dioxoles; Disease Models, Animal; Drug Synergism; Female; Immunization; Immunosuppression Therapy; Interferon-gamma; Mice, Inbred C57BL; Ovarian Neoplasms; Peritoneal Lavage; Programmed Cell Death 1 Receptor; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2015 |
Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Retrospective Studies; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Proliferation; Deoxycytidine; Dioxoles; Doxorubicin; Female; Gemcitabine; Humans; Mice; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Polyethylene Glycols; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cohort Studies; Dioxoles; Female; Humans; Middle Aged; Nausea; Ovarian Neoplasms; Prospective Studies; Tetrahydroisoquinolines; Trabectedin; Vomiting | 2017 |
Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2010 |
Trabectedin in ovarian cancer: could we expect more?
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2011 |
The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dioxoles; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin; Xenograft Model Antitumor Assays | 2011 |
Trabectedin and ovarian cancer: statistical trickery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin | 2011 |
Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin.
Topics: Adenocarcinoma, Clear Cell; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dioxoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Tetrahydroisoquinolines; Trabectedin | 2013 |
The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dioxoles; Drug Synergism; Female; Humans; Isoquinolines; Mice; Neoplasm Transplantation; Ovarian Neoplasms; Rhabdomyosarcoma; Tetrahydroisoquinolines; Trabectedin; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.
Topics: Animals; Antineoplastic Agents, Alkylating; Cattle; Cell Line, Tumor; Cell Survival; Culture Media; Dioxoles; Female; Humans; Isoquinolines; Ovarian Neoplasms; Serum; Tetrahydroisoquinolines; Trabectedin | 2004 |
Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chondrosarcoma; Dioxoles; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tetrahydroisoquinolines; Trabectedin | 2005 |
The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Dioxoles; DNA; DNA Repair; Female; Humans; Isoquinolines; Ovarian Neoplasms; Promoter Regions, Genetic; Temperature; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured | 2004 |
New agents and new formulations for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Dioxoles; Erlotinib Hydrochloride; Female; Humans; Isoquinolines; Ovarian Neoplasms; Predictive Value of Tests; Quinazolines; Recurrence; Remission Induction; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A | 2005 |
Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Dioxoles; DNA Repair; Female; Gene Expression Profiling; Humans; Ovarian Neoplasms; Protein Array Analysis; Tetrahydroisoquinolines; Trabectedin | 2008 |
Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Cell Division; Dioxoles; Drug Screening Assays, Antitumor; Female; Humans; Isoquinolines; Mice; Neoplasm Transplantation; Ovarian Neoplasms; Peritoneal Cavity; Tetrahydroisoquinolines; Trabectedin; Transplantation, Heterologous | 1998 |
High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Dioxoles; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Melanoma; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Ovarian Neoplasms; Tetrahydroisoquinolines; Trabectedin | 1999 |
Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dioxoles; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, MDR; Humans; Isoquinolines; Neoplasm Proteins; Ovarian Neoplasms; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles | 2000 |